Showing results (461-470 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|November 4, 2005
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecanMaki Ando, Yoshinori Hasegawa, Yuichi AndoInvestigational New Drugs|November 4, 2005
Cancer treatment and pharmacogenetics of cytochrome P450 enzymesRon H N van SchaikInvestigational New Drugs|January 1, 1994
A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) studyR B Weiss, B L Peterson, S L Allen, et al.Investigational New Drugs|January 1, 1984
Antitumor cell and antimetabolic effects of 5-ethyl-2'-deoxyuridine and 5'-substituted 5-ethyl-2'-deoxyuridine derivativesJ Balzarini, E De Clercq, G Kiefer, et al.Investigational New Drugs|January 1, 1984
Activity of Carbetimer in a human tumor cloning systemD L Kisner, P Mehta, G E Paget, et al.Investigational New Drugs|January 1, 1984
Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamideU Niemeyer, J Engel, G Scheffler, et al.Investigational New Drugs|January 1, 1984
Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide)D S Alberts, J G Einspahr, R Struck, et al.Investigational New Drugs|January 1, 1984
Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemiaD S Zaharko, J M Covey, G HörpelInvestigational New Drugs|January 1, 1984
Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumorsG Atassi, P Hilgard, J PohlInvestigational New Drugs|January 1, 1984
Experimental toxicology of ASTA Z 7557 (INN mafosfamide)J Pohl, P Hilgard, W Jahn, et al.Pageof 372